STARCOIN GROUP (00399) announced that following its October disclosure, the company signed a sponsored research and strategic advisory agreement with Scaling Lab on December 17, 2025, to further implement and strengthen collaborative measures with Johns Medical School. Key terms of the agreement include:

(1) Scaling Lab will conduct non-clinical and non-regulatory sponsored research on cardiovascular and cardiometabolic diseases (including diabetes), non-injectable diabetes treatment pathways, aquaporins (AQP), and related metabolic studies.

(2) Dr. Young and his team will provide strategic scientific advisory services to support the group’s R&D efforts in oral diabetes medications, oral peptide therapies, and drug delivery systems.

(3) Intellectual property generated by Scaling Lab will be owned by Johns Medical School, though the group will retain priority and commercially reasonable licensing rights, including first negotiation rights for global licensing of related technologies.

The collaboration with Scaling Lab, a globally renowned medical research institution affiliated with Johns Medical School, reflects the group’s commitment to high-quality research commercialization and is expected to deliver significant scientific and strategic advantages. Scaling Lab’s expertise in metabolic physiology, diabetes mechanisms, and aquaporin-related pathways provides a robust scientific foundation, complementing ongoing development in oral insulin and peptide therapies.

Dr. Young’s advisory role under the agreement will enhance the group’s ability to evaluate emerging technologies, optimize research directions, and accelerate innovation in non-injectable diabetes treatments. Partnering with top-tier biomedical research institutions like Johns Medical School will elevate the group’s scientific standing and facilitate future international collaborations.

The agreement grants the group favorable licensing negotiation rights for developed IP, potentially securing exclusive or preferential access to new technologies related to oral insulin and drug delivery systems. Additionally, the five-year research framework fosters sustained collaboration, knowledge transfer, and talent development, which may bolster the group’s long-term competitiveness in the global diabetes treatment market.

This agreement aligns with STARCOIN GROUP’s efforts to enhance R&D viability and sustainable growth.